Table 5.

Association between rs2839693 polymorphism and clinicopathological parameters

rs2839693	C/C	C/T	T/T	C/T + T/T
Age
> 49/≤ 49	180/129	63/43	6/3	69/46
OR (95% CI)	1.00 (references)	1.05(0.67–0.831)	1.43(0.37–6.89)	1.08(0.70–1.67)
p		0.831	0.615	0.745
BMI (kg/m2)
≥ 23/ < 23	117/192	41/65	4/5	78/101
OR (95% CI)	1.00 (references)	1.04(0.65–1.62)	1.31(0.32–5.06)	1.05(0.68–1.63)
p		0.881	0.689	0.811
Menstrual status
Yes/no	197/112	66/40	8/1	74/41
OR (95% CI)	1.00 (references)	0.94(0.60–1.49)	4.55(0.82–84.92)	1.03(0.66–1.61)
p		0.784	0.156	0.91
Tumor size (cm)
> 2/≤ 2	157/152	63/43	5/4	68/47
OR (95% CI)	1.00 (references)	1.42(0.91–2.23)	1.21(0.31–4.97)	1.40(0. 91–2.17)
p		0.126	0.779	0.128
Metastasis
Positive/negative	161/148	57/49	5/4	68/47
OR (95% CI)	1.00 (references)	1.07(0.69–1.67)	1.15(0.30–4.97)	1.40(0.91–2.17)
p		0.766	0.838	0.187
TNM Stage
III-IV/I-II	90/219	34/72	2/7	36/79
OR (95% CI)	1.00 (references)	1.15(0.71–1.84)	0.70(0.10–2.94)	1.11(0.69–1.76)
p		0.567	0.654	0.663
ER
Positive/negative	214/95	66/40	6/3	72/43
OR (95% CI)	1.00 (references)	0.73(0.46–1.17)	0.89(0.23–4.28)	0.74(0.48–1.17)
p		0.186	0. 868	0.195
PR
Positive/negative	186/123	52/44	3/6	55/60
OR (95% CI)	1.00 (references)	0.64(0.41–0.99)	0.33(0.07–1.27)	0.61(0.39–0.93)
p		0.046*	0.122	0.023*
Her-2
Positive/negative	133/176	46/60	2/7	48/67
OR (95% CI)	1.00 (references)	1.01(0.65–1.58)	0.38(0.06–1.59)	0.95(0.61–1.46)
p		0.949	0.23	0.809

OR odds ratio, CI confidence interval, BMI body mass index, TNM tumor mode metastasis, ER estrogen receptor, PR progesterone receptor, Her human epidermal growth factor receptor